Baxter International and Coherus Biosciences, Inc. have entered into an exclusive collaboration to develop and commercialize a biosimilar to etanercept (Enbrel) for Europe, Canada, Brazil and other markets. Coherus will conduct development and Baxter will make an upfront payment of $30 million and as much as $216 million based on development and regulatory milestones. The agreement also allows for development and commercialization of an alternative biosimilar to etanercept.   “The collaboration ...